Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

It has now been discovered that p53 is a potent inhibitor of angiogenesis and arteriogenesis. Inhibition of p53 stimulates angiogenesis, arteriogenesis and improves perfusion in limbs. Therefore, methods are provided for treating diabetic-induced ischemia in a subject in need thereof comprising locally administering a therapeutically effective amount of one or more p53 molecule inhibitors or analogs and derivatives thereof to a site of ischemic tissue in the subject. Methods are provided for improving limb perfusion in a subject in need thereof comprising locally administering a therapeutically effective amount one or more p53 inhibitors together with a therapeutic agent or separately from the therapeutic agent to cells of a limb of a subject in need thereof. Methods are also provided for improving ischemia-induced angiogenesis and arteriogenesis in method of improving ischemia-induced angiogenesis in tissue of a limb comprising administering a therapeutically effective amount one or more p53 inhibitors individually or in combination with another therapeutic to a subject in need thereof.

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows:

##STR00001##

wherein Y, R.sup.1, G, and Q are defined herein;
and

##STR00002##

wherein R.sup.11, R.sup.21, R.sup.41, R.sup.B1 and G.sup.1, are defined herein.

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows:

##STR00001##

wherein Y, R.sup.1, G, and Q are defined herein;
and

##STR00002##

wherein R.sup.11, R.sup.21, R.sup.41, R.sup.B1 and G.sup.1, are defined herein.

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed

Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed.